Today: 30 April 2026
Reckitt Benckiser shares slip after RBC downgrade as buybacks and dividend vote loom
15 January 2026
1 min read

Reckitt Benckiser shares slip after RBC downgrade as buybacks and dividend vote loom

London, Jan 15, 2026, 09:37 GMT — Regular session

  • Reckitt shares dipped in early London trading following RBC’s decision to downgrade its rating and slash the target price
  • RBC highlighted doubts over 2026 margins and the lingering impact of the Mead Johnson litigation
  • Investors are keeping an eye on a January 27 shareholder vote linked to a £1.6 billion special dividend

Shares of Reckitt Benckiser Group plc slipped Thursday, dropping 0.2% to 6,170 pence by mid-morning in London, following a downgrade from RBC Capital Markets. The broker flagged valuation concerns after the company sold its Essential Home unit.

The call comes at a tricky time for investors. Reckitt is seeking shareholder approval for a sizable one-off cash return and a share consolidation, even as the market awaits firmer guidance on profitability in 2026.

It’s crucial now since those two paths are diverging. A special dividend would deliver cash fast, yet “stranded costs” — overheads lingering after a sale — could squeeze margins until management adjusts the cost structure.

RBC analyst James Edwardes Jones flagged that the broker’s updated figures are “not the finished article,” pointing to missing guidance on margin expansion in 2026 post-Essential Home sale. He factored in a 60 basis point drop in EBIT margin — with one basis point equal to 0.01 percentage point — and included a £2 billion global settlement in his model for U.S. necrotising enterocolitis (NEC) claims tied to Mead Johnson. The first bellwether case is expected in February. Investing.com

Reckitt disclosed another modest buyback, acquiring 48,660 shares on Jan. 14 at a volume-weighted average price of 6,162.77 pence. The company plans to hold these shares in treasury. The filing updates total voting rights to 671,991,359, the number investors rely on for UK disclosure rules.

The company plans a special dividend of 235 pence per share, totaling around £1.6 billion. It also proposes a 24-for-25 share consolidation to keep the share price roughly stable post-dividend. Shareholders will vote on the proposal at a general meeting on Jan. 27, with the dividend slated for payment on Feb. 20 if approved.

A consolidation essentially resets the share count: investors end up with fewer shares, but each one should carry a higher value, assuming everything else stays the same. Traders, however, keep an eye on potential snags—like shifts in index weightings, fund mandates, and how seamlessly the process unfolds.

The key “but” remains: none of the major uncertainties have been resolved. If stranded costs hit margins harder than anticipated, or if the NEC litigation takes a negative turn, the market’s perception of this as a defensive, cash-return play could shift sharply.

Investors will be watching closely for broker follow-up after RBC’s move while also tracking price action near the 6,200 pence mark, now aligned with RBC’s target.

Coming up next: the Jan. 27 shareholder meeting to vote on the special dividend and consolidation. Then there’s the February NEC bellwether case, which RBC says might shape settlement discussions. Both events lead up to the Feb. 20 payout date.

Stock Market Today

  • Why Investors Are Focused on Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) Amid Growth and High Insider Ownership
    April 29, 2026, 10:29 PM EDT. Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) has attracted investor attention due to its strong financial performance and insider alignment. The company has delivered a compound annual EPS growth of 19% over the past three years, signaling sustained earnings momentum. Revenue growth and an improved EBIT margin, up by 6.6 percentage points to 11%, underscore operational strength. With insiders owning 78% of the firm, alignment between management and shareholders is notably high, reducing agency risk. Valued at ₹2.5 billion, the company appeals to investors favoring profitable, growing firms over speculative ventures without revenue or profit history. This combination of growth, profitability, and insider confidence makes Vaidya Sane a compelling pick in the Ayurvedic healthcare sector.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Experian PLC stock slips again: what to watch before the Jan. 21 trading update
Previous Story

Experian PLC stock slips again: what to watch before the Jan. 21 trading update

Lloyds hit with data watchdog questions as Barclays, NatWest buybacks keep UK bank shares in focus
Next Story

Lloyds hit with data watchdog questions as Barclays, NatWest buybacks keep UK bank shares in focus

Go toTop